197 related articles for article (PubMed ID: 3899034)
1. Postmarketing studies of drug efficacy.
Strom BL; Melmon KL; Miettinen OS
Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
[No Abstract] [Full Text] [Related]
2. Postmarketing studies of drug efficacy: when must they be randomized?
Strom BL; Miettinen OS; Melmon KL
Clin Pharmacol Ther; 1983 Jul; 34(1):1-7. PubMed ID: 6861430
[No Abstract] [Full Text] [Related]
3. [Critical study of methods of postmarketing drug surveillance].
Gut JP; Auriche M; Spriet-Pourra C; Juillet Y
Therapie; 1985; 40(5):313-9. PubMed ID: 3913048
[No Abstract] [Full Text] [Related]
4. Statewide test of a new postmarketing drug surveillance system.
Fisher S; Bryant SG; Solovitz BL; Kluge RM
Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
[No Abstract] [Full Text] [Related]
5. [Postmarketing surveillance of drugs].
Simon P; Soubrié C
Rev Prat; 1983 Jan; 33(1-2):23-8. PubMed ID: 6823538
[No Abstract] [Full Text] [Related]
6. [Is imputation in drug surveillance reliable?].
Girard M
Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
[No Abstract] [Full Text] [Related]
7. Adverse drug reactions.
Turner P
Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
[No Abstract] [Full Text] [Related]
8. [Drug monitoring].
Royer RJ
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
[No Abstract] [Full Text] [Related]
9. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
Goujard J
Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
[No Abstract] [Full Text] [Related]
10. [Necessity and difficulties of quantitative drug monitoring].
Lagier G; Dally S; Vincens M; Castot A
Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
[No Abstract] [Full Text] [Related]
11. [How to report side-effects of drugs?].
Guillaume JC
Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
[No Abstract] [Full Text] [Related]
12. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
Lagier G; Vincens M; Lefebure B; Frelon JH
Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
[No Abstract] [Full Text] [Related]
13. [Bayesian approach to the imputability of undesirable phenomena to drugs].
Auriche M
Therapie; 1985; 40(5):301-6. PubMed ID: 4095686
[No Abstract] [Full Text] [Related]
14. What you should know about FDA-USP Drug Product Problem Reporting Program.
McGinnis DM
Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
[No Abstract] [Full Text] [Related]
15. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
Lagier G; Vincens M; Castot A
Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
[No Abstract] [Full Text] [Related]
16. Critical reflection on the collection and evaluation of adverse drug reaction data.
Venulet J
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
[No Abstract] [Full Text] [Related]
17. Adverse drug reaction reporting.
Bosco LA
Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
[No Abstract] [Full Text] [Related]
18. [A network of regional correspondents for studying undesirable effects].
Haramburu F; Péré JC; Begaud B; Albin H
Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
[No Abstract] [Full Text] [Related]
19. [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods].
Péré JC; Godin MH; Bégaud B; Haramburu F; Albin H
Therapie; 1985; 40(5):307-12. PubMed ID: 4095687
[No Abstract] [Full Text] [Related]
20. The diagnosis of adverse medical events associated with drug treatment.
Stephens MD
Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
